• Maze Therapeutics stock is among today’s weakest performers. What’s behind MAZE decline?AMKD is a type of kidney disease caused by variants (changes) in the APOL1 (apolipoprotein L1) gene.The trial results showed a 35.6% mean reduction in urinary albumin-to-creatinine ratio (uACR) among broad AMKD patients treated with MZE829, with 50% of patients achieving a reduction of over 30%.uACR measures albumin (a blood protein) and creatinine (a waste product) in a urine sample to assess kidney function. A healt ...

Maze Therapeutics (NasdaqGM:MAZE) Update / briefing March 25, 2026 08:00 AM ET Company ParticipantsDebjit Chattopadhyay - Senior Managing DirectorHarold Bernstein - President of Research and Development and Chief Medical OfficerJason Coloma - CEOJulian Harrison - Managing DirectorLaura Chico - Managing DirectorMartin Auster - Managing DirectorSadia Rahman - VP of Biopharma Equity ResearchConference Call ParticipantsAnanda Ghosh - VP and Research AnalystAnupam Rama - Executive Director and Biotechnology Equi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) Commission File Number: 001-42490 MAZE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 171 Oyster Point Blvd., Suite 300 South San Francisco, California 94080 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ...

Exhibit 99.1 Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference call today at 8:00 am EDT Two Phase 2 proof-of-concept clinical trials evaluating MZE782 in PKU and CKD expected to initiate in 2026 Industry leader Neil Kumar, Ph.D., Founder and CEO of BridgeBio, ...

– At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients, 50% of the patients achieved a greater than 30% reduction in uACR, and treatment was well-tolerated – – The subgroup of AMKD patients with FSGS that were treated with MZE829 showed a 61.8% mean reduction in uACR – – Treatment of non-diabetic AMKD patients with MZE829 led to a clinically meaningful mean reduction in uACR from baseline of 48.6% – – Results provide first clinical proof-of-concept in genetically ...

Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference call today at 8:00 am EDT Two Phase 2 proof-of-concept clinical trials evaluating MZE782 in PKU and CKD expected to initiate in 2026 Industry leader Neil Kumar, Ph.D., Founder and CEO of BridgeBio, appointed to Maze Board of Directors Strong balance sheet with $360.0 million in cash, cash equivalents and mark ...

Summary of Maze Therapeutics FY Conference Call Company Overview - **Company**: Maze Therapeutics (NasdaqGM:MAZE) - **Focus**: Harnessing human genetics to develop small molecule drugs for kidney and metabolic diseases - **Current Stage**: Mid-stage clinical development with a cash runway extending into 2028 [2][3][22] Key Programs MZE-829 - **Indication**: APOL1-mediated kidney disease - **Patient Population**: Approximately 6 million individuals in the U.S. have variants causing the disease, with about 250,000 potentially benefiting from treatment [4][8] - **Mechanism**: Aims to be a best-in-class therapy, addressing the limitations of current standard care, which is ineffective for these patients [6][7] - **Clinical Development**: Phase 2 global study named HORIZON, focusing on urinary albumin to creatinine ratio (UACR) as a primary endpoint [15][20] - **Efficacy Goal**: Aiming for a 30% reduction in UACR to demonstrate clinical proof of concept [16][19] - **Safety Profile**: Favorable safety profile reported in previous studies, with a half-life of about 15 hours allowing for once-daily dosing [14][33] MZE-782 - **Indication**: Phenylketonuria (PKU) and potential chronic kidney disease (CKD) applications - **Mechanism**: Targets the toxic substrate phenylalanine, allowing for its excretion without relying on residual enzyme activity [48][49] - **Clinical Data**: Early data showed significant urinary phenylalanine excretion and potential for better outcomes compared to existing therapies [50][51] - **Next Steps**: Plans to initiate a Phase 2 study in PKU by mid-2026 [51] Market Opportunity - **Addressable Market**: The potential market for MZE-829 and MZE-782 is substantial, with estimates reaching billions in revenue if successful [41][58] - **Diagnosis and Testing**: Increased awareness and availability of genetic testing for APOL1-mediated kidney disease are expected to improve diagnosis rates [42][43] Industry Context - **Regulatory Landscape**: Discussion of potential accelerated approval pathways based on proteinuria reduction and eGFR slope [36][38] - **Competitive Landscape**: Other companies, such as Vertex and AstraZeneca, are also developing therapies for APOL1-mediated kidney disease, using UACR as a key endpoint [29][30] Additional Insights - **Patient Journey**: Understanding the unique progression of APOL1-mediated kidney disease, which manifests earlier and progresses more rapidly than typical chronic kidney disease [7][10] - **Genetic Insights**: The role of genetics in understanding disease mechanisms and developing targeted therapies is emphasized as a core strength of the company [34][56] Conclusion - Maze Therapeutics is positioned to potentially lead in the development of innovative therapies for kidney diseases, with significant upcoming data readouts and a strong pipeline that could address unmet medical needs in both kidney disease and metabolic disorders [21][22][58]

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present at the TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026 at 10:30 a.m. ET. A live webcast of the event will be available in the Investors section of ...

Company Overview - Maze Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule precision medicines for renal, cardiovascular, metabolic diseases, and obesity [5] - As of February 14, 2026, the company's stock price is $46.01, with a market capitalization of $2.21 billion and a net loss of $101.46 million over the trailing twelve months [4] Stock Performance - The stock has experienced a remarkable 284.06% price change over the past year, with a significant gain of 158% in 2025 following its IPO on January 31, 2025 [4][7] - After its IPO, Maze Therapeutics has shown consistent growth, achieving nine consecutive months of gains [7] Recent Insider Transaction - On February 2, 2026, Harold Bernstein, the Chief Medical Officer, exercised 15,000 stock options and sold the resulting shares for approximately $690,300, fully divesting his direct ownership [2][6] - This transaction was part of a 10b5-1 trading plan, which allows insiders to prearrange share transactions, and Bernstein still holds nearly 300,000 stock options post-transaction [6] Market Sentiment - Despite the recent insider sale, analysts on Wall Street consider Maze Therapeutics a strong buy, and the company continues to advance in clinical trials for multiple medicines [9]

Core Insights - Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for kidney and metabolic diseases [3] - The company will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026 [1] Company Overview - Maze Therapeutics utilizes human genetics to create novel small molecule precision medicines targeting kidney and metabolic diseases, including obesity [3] - The company operates its Compass™ platform to pursue genetically validated targets, integrating variant discovery and functionalization [3] - Maze's leading pipeline products include MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 for APOL1-mediated kidney disease, and MZE782, a SLC6A19 inhibitor advancing to Phase 2 for phenylketonuria and chronic kidney disease [3] Event Information - A live webcast of the upcoming presentation will be available on the Maze Therapeutics website and archived for 60 days [2]